title: Reply to the letter "thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy is a promising feasible therapeutic approach for myocardial infarction".
authors.affiliation: Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health, Farmington, CT, USA. Electronic address: nmaulik@uchc.edu.
authors.forename: Nilanjana
authors.initials: N
authors.lastname: Maulik
authors.affiliation: Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health, Farmington, CT, USA. Electronic address: mthirunavukkarasu@uchc.edu.
authors.forename: Mahesh
authors.initials: M
authors.lastname: Thirunavukkarasu
authors.affiliation: Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health, Farmington, CT, USA.
authors.forename: Vaithinathan
authors.initials: V
authors.lastname: Selvaraju
authors.affiliation: Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health, Farmington, CT, USA.
authors.forename: Sumanth C
authors.initials: SC
authors.lastname: Suresh
mesh_terms: D015316:Genetic Therapy; D006801:Humans; D059630:Mesenchymal Stem Cells; D009203:Myocardial Infarction / Q000628:therapy; D033581:Stem Cell Transplantation; D013879:Thioredoxins
chemical_list: D013879:Thioredoxins
keywords: Angiogenesis; Gene therapy; Mesenchymal stem cells; Myocardial infarction; Thioredoxin-1